[1]刘维①,赵艳**,吴琼,等.腔镜手术患者舒芬太尼靶控输注的药动学研究[J].中国微创外科杂志,2016,16(12):1131-1142.
　Liu Wei,Zhao Yan*,Wu Qiong*,et al.Pharmacokinetic Study of Sufentanil Administered by Target-controlled Infusion in Patients Undergoing Endoscopic Surgery[J].Chinese Journal of Minimally Invasive Surgery,2016,16(12):1131-1142.
点击复制

腔镜手术患者舒芬太尼靶控输注的药动学研究()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
16
期数:
2016年12期
页码:
1131-1142
栏目:
实验研究
出版日期:
2016-12-20

文章信息/Info

Title:
Pharmacokinetic Study of Sufentanil Administered by Target-controlled Infusion in Patients Undergoing Endoscopic Surgery
作者:
刘维①; 赵艳**; 吴琼; 郭向阳; 翟所迪①; 卢炜②; 任宇鹏②; 孙谊②
北京大学第三医院麻醉科，北京100083
Author(s):
Liu Wei;  Zhao Yan*;  Wu Qiong*;  et al.
*Department of Anesthesiology, Peking University Third Hospital, Beijing 100083, China
关键词:
舒芬太尼; 靶控输注; 药动学; 非线性混合效应模型; 液相色谱-质谱联用
Keywords:
Sufentanil; Target-controlled infusion; Pharmacokinetics; Nonlinear mixed-effect model; Liquid chromatography-mass spectrometry/mass spectrometry
文献标志码:
A
摘要:
目的探讨腔镜手术临床常用浓度舒芬太尼靶控输注(target-controlled infusion,TCI)的药动学特点。方法2011年6~9月，择期全麻下腔镜手术30例(24~65岁，ASA Ⅰ级或Ⅱ级)，应用内嵌Gepts药动学参数的TCI系统输注舒芬太尼，效应室靶浓度随机采用0.2、0.3和0.4 μg/L各10例，复合吸入七氟烷维持麻醉。于不同时点经桡动脉取血至停止TCI后24小时，以液相色谱-质谱联用法测定舒芬太尼的血药浓度。运用非线性混合效应模型分析舒芬太尼群体药动学数据。结果舒芬太尼TCI的药动学模型为三室模型，其药动学参数为：中央室容积(V1)=15.7 L，快速分布容积(V2)=50.4 L，慢速分布容积(V3)=213.0 L，稳态分布容积(Vdss)=279.2 L；药物总清除率(Cl1)=0.80 L/min，快速分布相清除率(Cl2)=1.09 L/min，慢速分布相清除率(Cl3)=0.27 L/min；快速分布半衰期(t1/2α)=4.6 min，慢速分布半衰期(t1/2β)=68.7 min，清除半衰期(t1/2γ)=739.5 min。年龄、性别和体重对药动学参数无显著影响（P>0.05）。结论腔镜手术患者临床常用浓度舒芬太尼TCI的药动学可用三室模型描述。年龄、性别和体重对药动学参数无显著影响。
Abstract:
ObjectiveTo study the pharmacokinetics of sufentanil administered by target-controlled infusion (TCI) at commonly used concentrations in patients undergoing endoscopic surgery. MethodsThe pharmacokinetic parameters of sufentanil TCI were investigated in 30 patients (ASA Ⅰ or Ⅱ), aged 24-65 years old, scheduled for elective endoscopic surgery under general anesthesia. Induction of anesthesia was started with sufentanil TCI, and target effect-site concentrations of sufentanil were randomly set at 0.2, 0.3 or 0.4 μg/L in each 10 cases, respectively. Anesthesia was maintained with sufentanil TCI, inhalation of sevoflurane and intermittent injection of rocuronium as needed to maintain muscle relaxation. Arterial blood samples were gathered at specific intervals from the beginning of TCI to 24 h after TCI. Plasma concentrations of sufentanil were measured by liquid chromatography-mass spectrometry/mass spectrometry (limit of quantitation was 2 ng/L). The population pharmacokinetic data of sufentanil were analyzed with the nonlinear mixed-effect model.ResultsThe pharmacokinetic pattern of sufentanil TCI was described as a three-compartment model with the following parameters: volume of the central compartment (V1)=15.7 L, volume of the rapidly equilibrating compartment (V2) = 50.4 L, volume of the slowly equilibrating compartment (V3)=213.0 L, volume of distribution at steady state (Vdss) = 279.2 L, total drug clearance (Cl1) = 0.80 L/min, rapid intercompartmental clearance (Cl2) = 1.09 L/min, slow intercompartmental clearance (Cl3) = 0.27 L/min, rapid distribution half-time (t1/2α) = 4.6 min, slow distribution half-time (t1/2β) = 68.7 min, and elimination half-time (t1/2γ) = 739.5 min. No significant relations to age, gender, or body weight were found for any of the pharmacokinetic parameters (P>0.05).ConclusionsThe pharmacokinetics of sufentanil TCI at commonly used concentrations in patients undergoing endoscopic surgery can be optimally described by a three-compartment model. No significant relations to age, gender, or body weight are found for any of the pharmacokinetic parameters.

参考文献/References:

[1]Struys MM,De Smet T,Glen JI,et al.The history of target-controlled infusion.Anesth Analg,2016,122(1):56-69.
[2]Short TG,Hannam JA,Laurent S,et al.Refining target-controlled infusion:an assessment of pharmacodynamic target-controlled infusion of propofol and remifentanil using a response surface model of their combined effects on bispectral index.Anesth Analg,2016,122(1):90-97.
[3]Kawano S,Okada H,Iwamuro M,et al.An effective and safe sedation technique combining target-controlled infusion pump with propofol,intravenous pentazocine,and bispectral index monitoring for peroral double-balloon endoscopy.Digestion,2015,91(2):112-116.
[4]Liu Y,Li M,Yang D,et al.Closed-loop control better than open-loop control of profofol TCI guided by BIS:a randomized,controlled,multicenter clinical trial to evaluate the CONCERT-CL closed-loop system.PLoS One,2015,10(4):e0123862.
[5]Jeleazcov C,Saari TI,Ihmsen H,et al.Changes in total and unbound concentrations of sufentanil during target controlled infusion for cardiac surgery with cardiopulmonary bypass.Br J Anaesth,2012,109(5):698-706.
[6]Bhavsar R,Sloth E,Folkersen L,et al.Sufentanil preserves hemodynamics and left ventricular function in patients with ischemic heart disease.Acta Anaesthesiol Scand,2011,55(8):1002-1009.
[7]Ji M,Tao J,Cheng M,et al.Endotracheal administration of sufentanil and tetracaine during awake fiberoptic intubation.Am J Ther,2016,23(1):e92-e97.
[8]Abdollahpour A,Azadi R,Bandari R,et al.Effects of adding midazolam and sufentanil to intrathecal bupivacaine on analgesia quality and postoperative complications in elective cesarean section.Anesth Pain Med,2015,5(4):e23565.
[9]Li B,Wang H,Gao C.Bupivacaine in combination with fentanyl or sufentanil in epidural/intrathecal analgesia for labor:a meta-analysis.J Clin Pharmacol,2015,55(5):584-591.
[10]Jove M,Griffin DW,Minkowitz HS,et al.Sufentanil sublingual tablet system for the management of postoperative pain after knee or hip arthroplasty:a randomized,placebo-controlled study.Anesthesiology,2015,123(2):434-443.
[11]Bovill JG,Sebel PS Blackburn CL,et al.The pharmacokinetics of sufentanil in surgical patients.Anesthesiology,1984,61(5):502-506.
[12]Zhao Y,Wu XM,Duan JL,et al.Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients.Chin Med J,2009,122(3):291-295.
[13]Gepts E,Shafer SL,Camu F,et al.Linearity of pharmacokinetics and model estimation of sufentanil.Anesthesiology,1995,83(6):1194-1204.
[14]吴琼,赵艳,郭向阳.舒芬太尼及其靶控输注的药代动力学研究进展.中国微创外科杂志,2013,13(10):941-943.
[15]王靖,杨承祥,王汉兵,等.舒芬太尼TCI系统用于心脏手术患者CPB结束至术毕的准确性.中华麻醉学杂志,2014,34(10):1231-1233.
[16]Manfio JL,Santos VJ,Lanchote VL,et al.Development and validation of an HPLC/MS/MS method for the determination of sufentanil and morphine in human plasma.J AOAC Int,2011,94(1):136-142.
[17]Nosseir NS,Michels G,Binder P,et al.Simultaneous detection of ketamine,lorazepam,midazolam and sufentanil in human serum with liquid chromatography-tandem mass spectrometry for monitoring of analgosedation in critically ill patients.J Chromatogr B Analyt Technol Biomed Life Sci,2014,12,973C:133-141.
[18]Choi L,Ferrell BA,Vasilevskis EE,et al.Population pharmacokinetics of fentanyl in the critically ill.Crit Care Med,2016,44(1):64-72.
[19]Bi SS,Deng CH,Zhou TY,et al.Remifentanil-sevoflurane interaction models of circulatory response to laryngoscopy and circulatory depression.Br J Anaesth,2013,110(5):729-740.
[20]Wesley MC,Pereira LM,Scharp LA,et al.Pharmacokinetics of tranexamic acid in neonates,infants,and children undergoing cardiac surgery with cardiopulmonary bypass.Anesthesiology,2015,122(4):746-758.
[21]Pandin PC,Cantraine F,Ewalenko P,et al.Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery.Anesthesiology,2000,93(3):653-661.
[22]Sherwin CM,Kiang TK,Spigarelli MG,et al.Fundamentals of population pharmacokinetic modelling:validation methods.Clin Pharmacokinet,2012,51(9):573-590.
[23]Bonate PL,Strougo A,Desai A,et al.Guidelines for the quality control of population pharmacokinetic-pharmacodynamic analyses:an industry perspective.AAPS J,2012,14(4):749-758.
[24]Mallaysamy S,Johnson MG,Rao PG,et al.Population pharmacokinetics of lamotrigine in Indian epileptic patients.Eur J Clin Pharmacol,2013,69(1):43-52.
[25]Wiczling P,Bienert A,Sobczyński P,et al.Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery.Pharmacol Rep,2012,64(1):113-122.
[26]Hudson RJ,Bergstrom RG,Thomson IR,et al.Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery.Anesthesiology,1989,70(3):426-431.
[27]Zhao Y,Duan JL,Wu XM,et al.Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. Chin Med J,2009,122(17):1979-1984.

备注/Memo

备注/Memo:
基金项目：北京大学第三医院中青年骨干基金项目（65476-01）**通讯作者，E-mail：zhaoyan2004@263.net①（北京大学第三医院药剂科，北京100083）②（北京大学药学院，北京100083）
更新日期/Last Update: 2017-03-09